Compounded Tirzepatide 2026
Updated May 5, 2026 — including the April 1 FDA enforcement shift, the April 30 503B exclusion proposal, and what June 29 means for compounded GLP-1.
- April 1, 2026: The FDA ended enforcement discretion for 503A pharmacies producing “essentially a copy” of tirzepatide and semaglutide at telehealth scale.
- April 30, 2026: The FDA formally proposed excluding tirzepatide, semaglutide, and liraglutide from the 503B bulks list — comment period open through June 29, 2026.
- Today: 503A pharmacies are restricted to true patient-specific compounding (documented allergies, custom strengths). Many telehealth providers continue under narrow exceptions; legal and compliance risk has increased materially.
- Always: Compounded tirzepatide is NOT an FDA-approved drug. The clinical trial efficacy of branded Zepbound (SURMOUNT-1: 20.2% weight loss) does NOT automatically transfer to compounded versions. Work with a licensed prescriber and a verifiable LegitScript / NABP-accredited compounding pharmacy.
What Is Compounded Tirzepatide?
Tirzepatide is the active molecule in Eli Lilly’s FDA-approved Zepbound (weight loss) and Mounjaro (type-2 diabetes). It is the only dual GIP + GLP-1 receptor agonist on the market, producing 20.2% average weight loss at 72 weeks in the SURMOUNT-1 trial.
Compounded tirzepatide is the same molecule produced by state-licensed 503A and 503B compounding pharmacies — NOT by Eli Lilly. The FDA permits compounding under specific exemptions (drug shortage status, individual patient medical necessity, or per state pharmacy board rules). Compounded versions can include the active ingredient alone, or stacked with B12, B6, NAD+, glycine, or L-carnitine depending on the provider’s formulation.
Compounded Tirzepatide Pricing (May 2026)
| Provider | Format | Monthly | Notes |
|---|---|---|---|
System Labs Best Value | Injectable | $179/mo | Lowest GLP-1 entry in our verified stack; longevity bundle (NAD+ / B-12 / Sermorelin) |
Embody Best Overall | Injectable + GLP-1 Gum | $149 first / $299 flat | Spring Forward $200 off + free shipping; flat refill price (no dose escalation fees) |
Gala Health Best 3-Mo Bundle | Injectable | $179–$199/mo (3-mo plan) | All-inclusive 3-month bundling; provider consults + async support + shipping included |
Care Bare Rx Best Multi-Vertical | Oral + Injectable | From $199/mo | Multi-vertical: $99 hair, $99 sexual health, $199 NAD+ standalone |
Eden Health | Injectable | $149 intro / $229–$249 | “Same Price at Every Dose” guarantee; month-to-month or 3-mo options |
Direct Meds Best for Sublingual | Sublingual Drops | $224.10/mo | Only verified provider with compounded sublingual tirzepatide; needle-free |
Direct Meds | Injectable | $297–$399/mo | Adjacent peptide menu (Sermorelin, NAD+, Epithalon) |
Pricing verified May 5, 2026 directly from each provider’s public site (Gronk-verified). Branded comparison: Zepbound list price $499–$1,086/fill; ~$1,498/mo through telehealth without insurance; as low as $25/mo with commercial insurance + savings card; LillyDirect cash-pay $299 starter dose, $399–$699 maintenance doses.
How to Choose a Safe Compounded Tirzepatide Provider
LegitScript or NABP certification
Confirms the compounding pharmacy meets baseline regulatory and quality standards.
503A vs 503B disclosure
503A pharmacies serve individual prescriptions. 503B "outsourcing facilities" produce in larger batches under stricter oversight. Either is acceptable; lack of clarity is a yellow flag.
Valisure third-party testing (bonus)
Some pharmacies submit batches to Valisure for independent purity / potency testing. This is the gold standard but rare.
Licensed prescriber required
Avoid any provider that ships without a real telehealth consultation and prescription. That is a major regulatory red flag.
Cold-chain shipping
Tirzepatide must remain refrigerated. Reputable providers ship with cold packs and clear handling instructions.
The May 2026 FDA Reality — A Two-Step Crackdown
FDA ended enforcement discretion for 503A “essentially-a-copy” compounding
Throughout 2024 and 2025, while the FDA-declared shortage of branded tirzepatide and semaglutide was active, 503A pharmacies operated under enforcement discretion that effectively allowed routine production of compounded copies for telehealth distribution. With the shortage officially resolved, the FDA ended that discretion on April 1, 2026. 503A pharmacies are now restricted to true patient-specific compounding — meaning a documented allergy, custom dosing strength, or other clinical justification for the individual patient. Routine telehealth-scale production of compounded copies of FDA-approved tirzepatide is no longer protected.
FDA proposed excluding tirzepatide, semaglutide, and liraglutide from the 503B bulks list
The 503B bulks list governs which active pharmaceutical ingredients FDA-registered outsourcing facilities are permitted to compound from bulk substance. On April 30, 2026, the FDA formally proposed excluding all three GLP-1 ingredients on the grounds that there is “no clinical need” for compounded versions when the FDA-approved branded products are commercially available.
The proposal entered a public comment period that closes June 29, 2026. If finalized after that, 503B outsourcing facilities would no longer be permitted to compound bulk tirzepatide, semaglutide, or liraglutide.
- Compounded tirzepatide is still available through telehealth providers operating under 503A patient-specific exceptions or via supply chains that have already adapted to the post-April reality.
- Pricing has held — the verified May 2026 stack still ranges $179–$399/mo. The crackdown has not yet materially shifted prices upward, but supply is tightening.
- Provider quality matters more than ever. Verify your provider sources from a LegitScript or NABP-accredited 503A pharmacy and is operating under a valid patient-specific compounding rationale, not a discontinued bulk-production model.
- If the June 29 proposal finalizes against compounded GLP-1, 503B-only providers will discontinue their compounded GLP-1 lines. 503A patient-specific compounding can continue for documented medical necessity, but supply chains may tighten further and prices may shift.
- Branded alternatives have shifted too. LillyDirect now sells branded Zepbound cash-pay vials at $299 (starter dose), scaling to $399–$699 maintenance doses. With commercial insurance + the manufacturer savings card, branded Zepbound can drop as low as $25/mo when covered. See our Zepbound vs Wegovy comparison for the full pricing breakdown.
We re-verify the FDA regulatory landscape and provider availability monthly. Last verified: May 5, 2026. The next material milestone is the June 29 close of the 503B exclusion comment period — we will publish a follow-up review within 7 days of any finalized rule. Subscribe to our news feed for updates.
Compare Compounded Tirzepatide Providers
All providers listed offer compounded tirzepatide. Pricing verified May 2026.
Top Compounded GLP-1 Telehealth Providers (May 2026)
Pricing accurate as of May 2026. Click a provider to see current pricing and start a consultation. We may earn a commission — at no extra cost to you. See our affiliate disclosure.
| Provider | Monthly Price | Rating | Action |
|---|---|---|---|
SkinnyRxBest Overall 503A compounded GLP-1 specialistCompounded Tirzepatide + Semaglutide (503A pharmacy) | $199–$399 | ★★★★★4.9 | View Best Offer |
TrimRx Online weight loss program with GLP-1 medicationGLP-1 weight loss program (catalog VERIFY) | From $179/mo | ★★★★☆4.5 | View Best Offer |
MEDViEditor’s Pick Reliable mid-tier compounded GLP-1Compounded Tirzepatide + Semaglutide | $179–$299 | ★★★★☆4.6 | View Best Offer |
DirectMedsBest for Sublingual Sublingual + injectable compounded GLP-1Compounded Sema + Tirz (injectable + sublingual), Sermorelin, NAD+, Epithalon | $179–$399 | ★★★★☆4.5 | View Best Offer |
Ivim HealthBest for Microdosing 360 wellness — branded + compounded + microdosing GLP-1Compounded Sema/Tirz/Liraglutide, microdosing GLP-1, Wegovy/Zepbound/Mounjaro/Ozempic/Saxenda, Wegovy Pill | From $75/mo + $74.99 program fee | ★★★★☆4.7 | View Best Offer |
Eden HealthBest Value Branded + compounded with intro pricingCompounded Sema + Tirz, branded GLP-1, NAD+ (5 formats), Sermorelin, hormone therapy | $149 intro / $229–$249 ongoing | ★★★★☆4.7 | View Best Offer |
Pricing and availability current as of May 2026. We earn a commission if you sign up through our links — at no additional cost to you. See our methodology for how we evaluate providers.
Compounded Tirzepatide vs Branded Zepbound — Quick Decision Guide
- Cost is the dominant factor (73-91% cheaper)
- You are uninsured or your insurance does not cover branded
- You are comfortable with non-FDA-approved medication under prescriber supervision
- Insurance covers the branded version
- You want FDA-approved batch-to-batch consistency
- You want the trial efficacy data (SURMOUNT-1: 20.2%) to apply directly
Find your compounded tirzepatide match
Take our 60-second quiz to get matched to the right compounded tirzepatide provider for your budget and preferences.
How this page is reviewed
Editorially reviewed by GLP1CompareHub Editorial Team. We are an independent affiliate publisher — we are not licensed medical providers and this site does not deliver medical advice. Every claim on this page is sourced to a verifiable origin (peer-reviewed study, FDA documentation, live brand-site crawl, or our Katalys partner dashboard).
Affiliate disclosure: We earn a commission when you sign up with a provider through our links — at no extra cost to you. We do not rank providers by what they pay us; we rank by patient fit. Full disclosure. Read our methodology · medical disclaimer.
Related Guides
Continue your research with these related independent reviews.